FDA Commissioner Marty Makary is resigning, according to Politico

The resignation of FDA Commissioner Marty Makary could signal potential shifts in regulatory approaches, particularly affecting sectors like biotech and pharmaceuticals. Market participants should watch for how this leadership change may influence policy direction and investor sentiment, especially in equities and related commodities impacted by FDA regulations. Given the market's focus, this development may create volatility in related assets, especially for biotech ETFs and pharmaceuticals.